CSL Behring’s new facility in Broadmeadows, Victoria, has been named the 2025 Facility of the Year by the International Society for Pharmaceutical Engineering (ISPE), in the Pharma 4.0 ...

ANDEMBRY® received manufacturing and marketing approval in Japan on February 20, 2025, for the prevention of acute attacks in hereditary angioedema (HAE) ANDEMBRY® is the first-in-class monoclonal ...

ST. GALLEN, Switzerland and SAN DIEGO, April 29, 2025 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are pleased to announce that the European Commission has approved the ...

For additional photos, logos and other branding elements, visit Brand.csl.com and Create an Account in the External Users Only box.

Thank you for your interest in CSL. We care about your questions and concerns. You can find the best way to contact us from the list below.

Are you interested in receiving our latest news? Simply fill out the form below to receive news alerts directly to your inbox. To receive releases from a specific CSL business unit, select customize ...

CSL Seqirus has today announced that construction of its new state-of-the-art manufacturing facility in Australia has reached its highest point, known as ‘topping out’. The world-class facility will ...